



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 1, 2021

Arthur T. Sands, M.D., Ph.D.  
President and Chief Executive Officer  
Nurix Therapeutics, Inc.  
1700 Owens Street, Suite 205  
San Francisco, CA 94158

**Re: Nurix Therapeutics, Inc.**  
**Draft Registration Statement on Form S-1**  
**Submitted February 22, 2021**  
**CIK No. 0001549595**

Dear Dr. Sands:

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at (202) 551-3635 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Jennifer J. Hitchcock, Esq.